Cost effectiveness analysis of antihypertensive captopril and amlodipine in patients with primary hipertension.

Hypertension is defined as high blood pressure with a systolic blood pressure of ≥140 mmHg and/or a diastolic blood pressure of ≥90 mmHg. Antihypertensives used to treat hypertension and keep blood pressure under control. Treatment of hypertension is a long-term treatment, even for a lifetime, therefore it can cause an financial burden for patients and health care providers. Because many classes of antihypertensives are available, it is necessary to choose an cost-effective antihypertensive. The purpose of this study was to find out the cost-effectiveness antihypertensive Captopril compared to Amlodipine in patients with primary hypertension at the Public Health Center in the Special Region of Yogyakarta. This study is a non-experimental observational cohort study with data collected retrospectively from medical records at the Public Health Center in the Special Region of Yogyakarta. This study included 545 patients, with 35 patients receiving Captopril 12,5 mg, 46 patients receiving Captopril 25 mg, 303 patients receiving Amlodipine 5 mg, and 161 patients receiving Amlodipine 10 mg. The results showed, based on the ACER value, Captopril 25 mg was found to be more cost-effective than Amlodipine 5 mg and Amlodipine 10 mg. Captopril 12,5 mg was shown to be more cost-effective than Amlodipine 10 mg, with an ICER value of 8.360 IDR reached when comparing Captopril 12,5 with Amlodipine 5 mg. [ABSTRACT FROM AUTHOR]